This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems? (ECTAug)

This study has been withdrawn prior to enrollment.
(PI deceased; study did not start.)
Information provided by (Responsible Party):
Jerrry L Lewis, University of Iowa Identifier:
First received: October 1, 2009
Last updated: March 21, 2017
Last verified: March 2017
The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.

Condition Intervention
Major Depressive Disorder Drug: memantine Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression

Resource links provided by NLM:

Further study details as provided by Jerrry L Lewis, University of Iowa:

Primary Outcome Measures:
  • Assessment of whether Memantine protects memory and cognitive impairment caused by ECT. [ Time Frame: 6 to 8 weeks ]

Secondary Outcome Measures:
  • Whether memantine will improve response of Depression to Electroconvulsive therapy. [ Time Frame: 6-8 weeks ]

Enrollment: 0
Actual Study Start Date: November 2009
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Memantine arm
Patient receiving ECT and Memantine
Drug: memantine
patient will receive 5mg daily for 7day then 10 mgm daily
Other Name: Namenda
Placebo Comparator: placebo
25 patients receiving ECT will will receive placebo
Drug: memantine
patient will receive 5mg daily for 7day then 10 mgm daily
Other Name: Namenda
Drug: Placebo
will give placebo that looks like memantine

Detailed Description:
Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Meets criteria for Major Depressive disorder

Exclusion Criteria:

  • Neurological disease
  • Mental retardation
  • Seizure disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00988663

United States, Iowa
University of Iowa hosptitals and clinic
Iowa City, Iowa, United States, 50208
Sponsors and Collaborators
Jerrry L Lewis
Principal Investigator: Jerry L Lewis, MD University of Iowa Hospitals and Clinic
  More Information

Responsible Party: Jerrry L Lewis, Principal Investigator, University of Iowa Identifier: NCT00988663     History of Changes
Other Study ID Numbers: Memantine ECT trial
Study First Received: October 1, 2009
Last Updated: March 21, 2017

Keywords provided by Jerrry L Lewis, University of Iowa:
electroconvulsive therapy
cognitive function

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents processed this record on September 19, 2017